Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34578584

about

Discoidin Domain Receptors: Potential Actors and Targets in Cancer Targeting Src family kinases in anti-cancer therapies: turning promise into triumph Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Regulation of SRC family kinases in human cancers Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.An update on dual Src/Abl inhibitors.Phase II study of dasatinib in patients with advanced non-small-cell lung cancer Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Response to combined molecular targeting: defining the role of P-STAT3.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Src-signaling interference impairs the dissemination of blood-borne tumor cells Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.Activation of abl family kinases in solid tumors.New targetable oncogenes in non-small-cell lung cancer.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma Targeting genomic alterations in squamous cell lung cancer.The current state of the art of quantitative phosphoproteomics and its applications to diabetes research

P2860

Q26751157-54DCAC86-C338-4F47-8EF7-F7D0BA997C54 Q27025646-F89920AB-5AD3-463E-9B90-366D89C912AD Q27851720-2A789888-1674-4580-9B2C-D643DA861152 Q28243770-75A8BC24-63E1-4CE8-BD8C-245651110B4D Q28250096-DBCD5F76-E863-417C-B5C4-E3D3ED193721 Q28542671-E4532B9F-1B3B-49E4-8D14-5189296C1F04 Q30278774-A0BCA9EB-A870-4625-9146-E1011CAB3BE7 Q30424531-03A5A4A5-D97C-405D-BBD5-8DAEBB935FEF Q33770326-66F2EBEE-5D5B-408F-82DD-D8BCDEDB650B Q33828409-2B658D88-F1FC-4D3E-BF7C-82B6B08C2614 Q33940893-F0F1275D-5790-4A79-A90D-DB260B0F44A9 Q33992604-12160982-A0AA-445D-801E-88076890F6F3 Q34099289-CD784A91-448C-443D-88FA-B77D0C87EDEC Q34121339-F5BB8234-F112-4DA8-B137-BEA00E151251 Q34270677-A1454800-230C-46C5-B7BA-529B78D40EDD Q34281221-7DB32D9F-43F6-42CF-A40F-5A2CE03EC342 Q34301120-118863BB-3167-4F91-B495-16CE386CFA81 Q34458274-E7540646-0D7A-4A87-BD2E-4843DF014C17 Q34667764-8E68106B-7177-432E-A8E7-575951EE50F4 Q34747847-FD9D4DFD-2D73-46F4-A0AE-A93CA2373359 Q34754045-EC7C0A04-DE0D-4649-9C0E-28E19902EFE2 Q35077627-BB2A066D-AE14-498C-AF3B-FCE22883CC57 Q35146581-2C5FA7A6-308C-4267-B7CB-1E59230F0688 Q35584482-60302912-FA7C-4F8F-A6C3-D5E2D6B5EAE6 Q35587056-EAC804CD-D364-4E14-9D0F-1D0CEE0764C3 Q35592279-5C615D89-6595-4717-A29D-90C5107D47C6 Q35659675-83BF05C9-82C3-4751-A151-FFAE7F24D4CD Q35829847-E7FC5057-CC64-4C8C-A040-5D34A0D15ACB Q35999362-1E351684-EEE1-45EB-AF8D-8E3423F7D045 Q36109785-78D6B673-4D63-4523-B502-ADB6BCEA37E8 Q36140620-18530637-6DFA-43B0-881B-364E49C30508 Q36153123-67A10601-E205-4525-80DF-7A7F4003D59B Q36389868-06A56041-6794-42FC-BF62-DAEEDE75109C Q36443421-65B14E6B-B258-4D76-8E51-66661D908240 Q36660677-18D71CAF-9756-445A-B0DE-C3B69C2419FF Q36850900-2F31775F-631A-445A-BFB0-53512EB6733B Q36939668-CD905404-DF00-4B23-9F8C-E10D5B92D6DE Q36949546-95D8ABBB-C98A-4A56-B214-5670905B3587 Q37068767-C8CDB22A-E238-4176-9B78-424682683E5A Q37080936-7EBA77C6-589A-4B74-81A4-66D6B72ECC93

P2860

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34578584

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@ast

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@en

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@nl

type

label

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@ast

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@en

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@nl

prefLabel

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@ast

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@en

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@nl

P1433

Q34578584-7A35AEC0-3AC0-452D-AA2D-E502EC569FA2

P1476

Q34578584-5A1B1CE2-EF16-4B09-A549-BACEC746F321

P2093

Q34578584-0029F0BF-6BA4-4073-A8DC-383A730F7D2C

Q34578584-179CE8E5-4261-4D77-95B9-F78E181F1355

Q34578584-247E78EE-3C2D-4F03-93B9-F590ED72FAAC

Q34578584-2898E47C-7D81-4528-8AF9-30DDB43368A6

Q34578584-2D4899B6-4965-48B6-93E8-84822188B8BE

Q34578584-2E4407AC-023E-41E7-A14E-F5D29F228EA3

Q34578584-3863D0D5-0A13-44DE-81C6-B0F67E25F2D4

Q34578584-3A969A18-D3C9-4424-AC3F-A7588F27C360

Q34578584-45CFFBBE-E4B1-4910-90B1-1BE5159517EE

Q34578584-4920E504-FCC8-4688-8FBA-CCE94200FB34

P2860

Q34578584-016EB570-3250-42D6-936E-8908559EAD30

Q34578584-03839D38-EDBB-453C-BE16-513588C8BF7A

Q34578584-0883B4CF-BD3C-487A-A9E9-1EFDE97AE0DE

Q34578584-0A9DE558-29E6-4CCA-8A4D-FE0A0FB4DE19

Q34578584-0ADE3C7B-E8F8-4A2A-AC07-34E5B234B58B

Q34578584-0C37BA5B-1CB0-400D-A0CF-57AC97F7F6DF

Q34578584-119AAA3F-F02F-41CD-B283-91C835912B48

Q34578584-154D667C-EFCE-4197-96B3-4827A75A1183

Q34578584-1E50E1FD-0488-4C4F-9588-D34FCF017BD8

Q34578584-20B5E507-BB4D-4769-A7C0-26A3C0E790BD

P304

Q34578584-DED1BE26-F506-4245-88F6-044E191C0262

P31

Q34578584-03FF6403-0267-46AE-8099-B426CF8DF54D

P356

Q34578584-694FD47D-34A3-493F-9596-2DC2AA92031D

P407

Q34578584-DCF71CB1-394E-4096-B096-6D1301E16746

P433

Q34578584-0B65E48A-7A97-4CBC-89FB-A27A1A2B3340

P478

Q34578584-205D62C1-20B9-464B-96C2-D6FAB1B9DF7F

P577

Q34578584-386F49EF-1F62-45B5-8937-BF90618D7C3F

P5875

Q34578584-5B9EABB4-45FA-4E6F-9766-A5D9399AF5BA

P698

Q34578584-F96409CC-2A29-4132-8604-E041200405E8

P932

Q34578584-641CADB9-AE32-4A14-9540-E11FD56C53CF

P356

JCO.2009.25.4029

P1433

Journal of Clinical Oncology

P1476

Phase I/II study of the Src in ...... ed non-small-cell lung cancer.

@en

P2093

Alberto Chiappori

http://www.w3.org/2001/XMLSchema#string

Anthony Neuger

http://www.w3.org/2001/XMLSchema#string

Bhupendra Rawal

http://www.w3.org/2001/XMLSchema#string

Charles Williams

http://www.w3.org/2001/XMLSchema#string

Eric B Haura

http://www.w3.org/2001/XMLSchema#string

George Simon

http://www.w3.org/2001/XMLSchema#string

Gerold Bepler

http://www.w3.org/2001/XMLSchema#string

Jhanelle Gray

http://www.w3.org/2001/XMLSchema#string

Lanxi Song

http://www.w3.org/2001/XMLSchema#string

Leticia Tetteh

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Erlotinib in previously treated non-small-cell lung cancer

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

A renaissance for SRC

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.

STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.

c-Src and cooperating partners in human cancer.

P304

1387-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.4029

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416929

http://www.w3.org/2001/XMLSchema#string

P698

20142592

http://www.w3.org/2001/XMLSchema#string

P932

3040065

http://www.w3.org/2001/XMLSchema#string